← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA4708.2x12.7x19.1x
EV / LTM revenue6970.9x1.9x3.6x
Premium to unaffected price64920%32%52%
Premium to 30-day VWAP12220%37%50%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
041812009: 5 deals, 1 clean on every measure200952010: 66 deals, 16 clean on every measure2010662011: 76 deals, 46 clean on every measure2011762012: 75 deals, 64 clean on every measure2012752013: 81 deals, 71 clean on every measure2013812014: 55 deals, 50 clean on every measure2014552015: 61 deals, 57 clean on every measure2015612016: 66 deals, 63 clean on every measure2016662017: 60 deals, 51 clean on every measure2017602018: 67 deals, 62 clean on every measure2018672019: 63 deals, 59 clean on every measure2019632020: 51 deals, 43 clean on every measure2020512021: 72 deals, 62 clean on every measure2021722022: 60 deals, 54 clean on every measure2022602023: 57 deals, 43 clean on every measure2023572024: 69 deals, 59 clean on every measure2024692025: 57 deals, 47 clean on every measure2025572026: 32 deals, 24 clean on every measure202632
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 18.8x median across 49 dealsHealthcare18.8xn=49Technology: 18.2x median across 96 dealsTechnology18.2xn=96Financials: 17.7x median across 11 dealsFinancials17.7xn=11Real Estate: 17.2x median across 20 dealsReal Estate17.2xn=20Business Services: 13.2x median across 27 dealsBusiness Services13.2xn=27Industrials: 12.9x median across 73 dealsIndustrials12.9xn=73Utilities: 10.8x median across 37 dealsUtilities10.8xn=37Materials: 9.7x median across 22 dealsMaterials9.7xn=22Other: 9.5x median across 19 dealsOther9.5xn=19Energy: 9.5x median across 22 dealsEnergy9.5xn=22Consumer & Retail: 9.5x median across 74 dealsConsumer & Retail9.5xn=74Media & Telecom: 9.4x median across 20 dealsMedia & Telecom9.4xn=20
Deals by sector
Technology: 226 dealsTechnology226Healthcare: 177 dealsHealthcare177Industrials: 136 dealsIndustrials136Consumer & Retail: 117 dealsConsumer & Retail117Financials: 106 dealsFinancials106Business Services: 66 dealsBusiness Services66Real Estate: 51 dealsReal Estate51Utilities: 43 dealsUtilities43Materials: 42 dealsMaterials42Energy: 40 dealsEnergy40Media & Telecom: 40 dealsMedia & Telecom40Other: 29 dealsOther29
Deals by buyer type
Financial sponsor: 123 dealsFinancial sponsor123Strategic: 1073 dealsStrategic1073Management / founder: 2 dealsManagement / founder2Controlling holder: 10 dealsControlling holder10Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 913 dealsUnclassified913
Deals by enterprise value
Under $250m: 361 dealsUnder $250m361$250m to $1bn: 262 deals$250m to $1bn262$1bn to $5bn: 304 deals$1bn to $5bn304$5bn to $20bn: 117 deals$5bn to $20bn117Over $20bn: 20 dealsOver $20bn20Not computed: 9 dealsNot computed9
Deals by industry code
Business Services & Software: 179 dealsBusiness Services & Sof…179Chemicals, Pharmaceuticals & Allied Products: 120 dealsChemicals, Pharmaceutic…120Electronics & Electrical Equipment: 99 dealsElectronics & Electrica…99Instruments, Medical Devices & Optical Goods: 70 dealsInstruments, Medical De…70Industrial Machinery & Computers: 43 dealsIndustrial Machinery & …43Electric, Gas & Sanitary Services: 43 dealsElectric, Gas & Sanitar…43Holding & Other Investment Offices: 38 dealsHolding & Other Investm…38Depository Institutions: 37 dealsDepository Institutions37Insurance Carriers: 35 dealsInsurance Carriers35Communications: 32 dealsCommunications32
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Prometheus Biosciences, Inc.
2023-04-15 · Public merger · $200.00 a share
Held out of the multiples: EV / LTM revenue 2198.1x above 60x
Merck & Co., Inc.
Strategic
Healthcare$8.8bnn.a.2198.1x
75%
DEFM14A
All cash
National Instruments Corp
2023-04-12 · Public merger · $60.00 a share
Emerson Electric Co.
Strategic
Technology$8.3bn26.7x4.8x
49%
7% to VWAP
DEFM14A
All cash
Tessco Technologies Inc
2023-04-11 · Public merger · $9.00 a share
Alliance USAcqCo 2, Inc.
Strategic
Industrials$82m45.7x0.2x
91%
DEFM14A
All cash
GasLog Partners LP
2023-04-06 · Take-private · $5.37 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value
Board book on file →
Saturn Merger Sub LLC
Strategic
Industrials$278mn.a.n.a.
24%
SC 13E3
All cash
Heska Corp
2023-03-31 · Public merger · $120.00 a share
Antech Diagnostics, Inc.
Strategic
Healthcare$1.2bnn.a.4.6x
23%
DEFM14A
All cash
Cvent Holding Corp.
2023-03-14 · Public merger · $8.50 a share
Held out of the multiples: EV / LTM EBITDA 91.6x outside 1x to 75x
Capstone Borrower, Inc.
Strategic
Technology$4.2bn91.6x6.7x
n.a.
DEFM14A
All cash
Seagen Inc.
2023-03-12 · Public merger · $229.00 a share
Pfizer Inc.
Strategic
Healthcare$41bnn.a.20.9x
42%
DEFM14A
All cash
Radius Global Infrastructure, Inc.
2023-03-01 · Public merger · $15.00 a share
Held out of the multiples: EV / LTM EBITDA 381.3x outside 1x to 75x
Apw Opco LLC
Strategic
Real Estate$2.7bn381.3x19.7x
28%
DEFM14A
All cash
Radius Global Infrastructure, Inc.
2023-03-01 · Public merger · $15.00 a share
Held out of the multiples: EV / LTM EBITDA 381.3x outside 1x to 75x
Apw Opco LLC
Strategic
Real Estate$2.7bn381.3x19.7x
28%
DEFM14A
All cash
Gold Flora Corp.
2023-02-21 · Public merger · $10.00 a share
MergerSub 1
Strategic
Other$1.0bnn.a.12.6x
n.a.
DEFM14A
All cash
Cardiovascular Systems Inc
2023-02-08 · Public merger · $20.00 a share
Abbott Laboratories
Strategic
Healthcare$707mn.a.3.0x
50%
44% to VWAP
DEFM14A
All cash
Oak Street Health, Inc.
2023-02-07 · Public merger · $39.00 a share
CVS Pharmacy, Inc.
Strategic
Healthcare$10bnn.a.4.6x
n.a.
DEFM14A
All cash
Sisecam Resources LP
2023-02-01 · Take-private · $25.00 a share
Board book on file →
Sisecam Resource Partners LLC
Strategic
Materials$480m3.0x0.7x
40%
40% to VWAP
SC 13E3
All cash
Volta Inc.
2023-01-17 · Public merger · $0.86 a share
Shell USA, Inc.
Strategic
Industrials$160mn.a.2.9x
18%
DEFM14A
All cash
DCP Midstream, LP
2023-01-05 · Take-private · $41.75 a share
Board book on file →
Phillips 66 Project Development Inc.
Strategic
Utilities$14bn12.6x0.9x
20%
25% to VWAP
SC 13E3
All cash
Aerojet Rocketdyne Holdings, Inc.
2022-12-17 · Public merger · $58.00 a share
L3Harris Technologies, Inc.
Strategic
Industrials$4.6bn18.6x2.1x
n.a.
DEFM14A
All cash
Apollo Endosurgery, Inc.
2022-11-29 · Public merger · $10.00 a share
Boston Scientific
Strategic
Healthcare$383mn.a.5.3x
67%
DEFM14A
All cash
Opiant Pharmaceuticals, Inc.
2022-11-13 · Public merger · $20.00 a share
Indivior Inc.
Strategic
Healthcare$80mn.a.3.6x
111%
DEFM14A
All cash
Benefitfocus, Inc.
2022-11-01 · Public merger · $10.50 a share
Voya Financial, Inc.
Strategic
Technology$310m20.1x1.2x
67%
DEFM14A
All cash
Atlas Corp.
2022-10-31 · Take-private · $15.50 a share
Held out of the multiples: equity value 3,829 vs fee-table value 1
Board book on file →
Not named in the filing
Strategic
Industrials$7.8bn6.9x4.8x
34%
8% to VWAP
SC 13E3
All cash
Altra Industrial Motion Corp.
2022-10-26 · Public merger · $62.00 a share
Regal Rexnord Corporation
Strategic
Industrials$4.9bn25.0x2.5x
66%
73% to VWAP
DEFM14A
All cash
UserTesting, Inc.
2022-10-26 · Public merger · $7.50 a share
Thunder Holdings, LLC, Inc.
Strategic
Technology$921mn.a.n.a.
95%
DEFM14A
All cash
Myovant Sciences Ltd.
2022-10-23 · Take-private · $27.00 a share
Board book on file →
Sumitomo Pharma Co., LTD.
Strategic
Healthcare$2.2bnn.a.6.7x
50%
48% to VWAP
SC 13E3
All cash
Continental Resources, Inc
2022-10-16 · Take-private · $74.28 a share
Board book on file →
Omega Acquisition, Inc.
Strategic
Energy$31bn4.6x3.6x
n.a.
9% to VWAP
SC 13E3
All cash
Albertsons Companies, Inc.
2022-10-13 · Public merger · $34.10 a share
The Kroger Co.
Strategic
Consumer & Retail$23bn5.3x0.3x
33%
30% to VWAP
DEFM14C
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More